The American Diabetes Association (ADA) 75th Scientific Sessions will be held in Boston, MA from June 5-9, 2015. Abstracts will not be online until May 29. The most salient presentations this year deal with safety details in incretin cardiovascular outcomes trials (CVOTs), data from some of the newer GLP-1 agonists that will help define their profiles, Phase III details from basal insulin LY2605541, first data from a couple insulin biosimilars, and new Phase II data in diabetic nephropathy. We highlight these and several other presentations in the planner. In addition, safety concerns were recently raised by the FDA over the SGLT2 inhibitors, and while there is not a special presentation on the topic in the schedule, it is likely to come up during some of the sessions. Our post- ADA report will, of course, include additional presentations, as well. In anticipation of the CVOT presentations, the planner includes an overview from Citeline on the ongoing cardiovascular safety studies of the DPP-IV inhibitors and GLP-1 agonists, along with their other trials and development pipeline. Citeline will be contributing additional analyses on other topics to the post-ADA report. Drugs Highlighted:

• Incretin's Cardiovascular Outcomes Trials (CVOTs): Januvia, Lyxumia


• Insulins: LY2605541, weekly insulins


• GLP-1 Agonists and Related: ITCA-650, HM11260C, HM12525A, and BKR-013


• GLP-1 Agonist/Insulin Combinations: Xultophy and LixiLan


• SGLT Inhibitors: SaxaDapa FDC, Sotagliflozin and Jardiance


• Diabetic Nephropathy: Baricitinib and NOX-E36


• Dyslipidemia: Praulent and Repatha


• Other Mechanisms: Imeglimin

To download the full conference planner in PDF and Excel, click the link at the top of the page. For our disclosures, please read the BioMedTracker Research Standards.